Clinical Evaluation of the efficiency of allogeneic cord blood transfusion in patients with autism

Abstract

Autism spectrum disorders (ASD) is found in 1 case per 160 children and increases annually. The etiology of ASD has not yet been identified, and therefore no effective treatment is available. The therapy is focused on rehabilitation, psychological and pedagogical methods that increase patients' socialization. According to the latest findings, immune response disorders and ischemic brain damage are detected in ASD pathogenesis. In regard to this, a clinical study was conducted to assess the safety and efficacy of transfusion of allogeneic cord blood cells, as they participate in the regulation of the immune response and stimulation of neo-angiogenesis. A total of 20 children participated in the study (10 in control and 10 with the study group). Cell transfusion was performed three times with an interval of 1 month in the amount of 8-10х 107/per kg of patient weight. Efficiency and safety were assessed by the general condition of children, assessment of disease severity by ATEC scale, cytokine levels in plasma (IL1b, IL6, TNF-alpha, IL8, y-IFN) and immune status (CD3+; CD3+CD8+; CD3+CD4+; CD16+CD56+ and CD19+) before and after treatment, observation period - 12 months The study proved the safety of the method, the reduction of the disease severity by ATEC. No significant changes in cytokine profile and immune status were detected.

Keywords

autism / hematopoietic cord blood cells / stem cells / transfusion

References

[1] Информационные бюллетени. Расстройства аутистического спектра (РАС): сайт ВОЗ. [Электронный ресурс]. 2020. Дата обновления: 07.11.2019. URL:https://www.who.int/ru/news-room/fact-sheets/ detail/autism-spectrum-disorders (дата обращения: 10.03.2020)

[2] Onore C., Careaga M., Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav. Immun. 2012; 26(3): 383-92

[3] Ashwood P., Corbett B.A., Kantor A. et al. In search of cellular immuno-phenotypes in the blood of children with autism. PLoS One 2011; 6(5): e19299.

[4] Enstrom A.M., Lit L., Onore C.E. et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav. Immun. 2009; 23(1): 124-33.

[5] Masi A., DeMayo M.M., Glozier N. et al. An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options. Neurosci. Bull. 2017; 33(2): 183-93.

[6] Siniscalco D., Antonucci N. Cellular therapy for autism spectrum disorder: a step forward to the optimal treatments. Ann. Transl. Med. 2019; 7 Suppl 3: S110.

[7] Park D.H., Borlongan C.V., Willing A.E. et al. Human umbilical cord blood cell grafts for brain ischemia. Cell Transplant. 2009; 18(9): 985-98.

[8] Wilcox J., Tsuang M.T., Ledger E. et al. Brain perfusion in autism varies with age. Neuropsychobiology 2002; 46(1): 13-6.

[9] Dawson G., Sun J.M., Davlantis K.S. et al. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. Stem Cells Transl. Med. 2017; 6(5): 1332-9.

[10] Frye R.E. Behaviorally associated changes in neuroconnectivity following autologous umbilical cord blood infusion in young children with autism spectrum disorder. Ann. Transl. Med. 2019; 7 Suppl 3: S123.

[11] Chez M., Lepage C., Parise C. et al. Safety and observations from a placebo-controlled, crossover study to assess use of autologous umbilical cord blood stem cells to improve symptoms in children with autism. Stem Cells Transl. Med. 2018; 7(4): 333-41.

RIGHTS & PERMISSIONS

Eco-Vector